tranexamic acid Capsules 500 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
Bangladesh
GMP approvals
WHO
Manufacturer #20899
This company is a large, fast-growing pharmaceutical organization with over two decades of experience. They produce a wide range of generic and specialty medicines targeting various therapeutic areas, including infectious diseases, inflammatory skin disorders, and cardiovascular health. Their product portfolio includes prescription medications, oral emulsions, syrups, and suspensions. The company holds several GMP certifications and has a robust manufacturing infrastructure with state-of-the-art formulation units and a vast distribution network spanning across the EU and North America. They are also actively expanding into emerging markets in Asia and Latin America.
Tranexamic acid is a coagulation modifier class medication that is used to prevent blood loss after major trauma, factor IX deficiency, hemophilia type A, melasma, nosebleeds, menorrhagia, and menstrual disorders. Manufacturing companies produce it as both standalone medication and in combination drug formulations, along with ingredients such as etamsylate and mefenamic acid. Suppliers market it in the forms of 100mg/ml solution for intravenous injection and 500mg tablets. In use for over 50 years, tranexamic acid is an inexpensive and widely used treatment. The World Health Organisation has included it in its list of Essential Medicines that contains the safest and most effective drugs recommended for a health system. Major pharmaceutical manufacturers and supplies of tranexamic acid include Pfizer and Sanofi-Aventis. Tranexamic acid is available in both trade name and generic formulations. Buyers are advised that online sellers may attempt to market fraudulent versions of the generic drug, whereas Pipeline Pharma, through its pre-auditing and quality control procedures ensures that only verified manufacturers and wholesalers enter our online marketplace, offering you a risk-free B2B pharmaceutical sales platform.